Actonel® (Risedronate) is a risedronate sodium tablet manufactured by Procter & Gamble Pharmaceuticals for the treatment of osteoporosis. Actonel® is a class of bisphosphonates, developed in 1960 by Warner Chilcott, LLC of New Jersey. Negative side effects began to be reported rather quickly; however, not until 2008 did the FDA tighten warnings to patients and physicians.
The most dangerous side effects reported regarding the use of Actonel® is musculoskeletal pain and long term damage. A direct link has been reported with Actonel® use and spontaneous femur fractures. More recently, Actonel® use has been linked to the development of esophageal ulcers and several cancers, including esophageal cancer. The FDA gave instructions to physicians on patient education after concerns that the warning labels did not seem to be helping patients become aware of the potential dangerous side effects.